A clinical and biochemical assessment of methotrexate in rheumatoid arthritis
| Autor: | T. J. Tait, Howard A. Bird, C. Astbury, P. Le Gallez |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
medicine.medical_specialty
Pharmacology Arthritis Rheumatoid chemistry.chemical_compound Rheumatology Internal medicine medicine Humans In patient Dyspepsia Nonsteroidal business.industry Maintenance dose Nausea General Medicine medicine.disease Clinical trial Methotrexate chemistry Rheumatoid arthritis Female Stomatitis Aphthous business medicine.drug |
| Zdroj: | Clinical Rheumatology. 13:75-79 |
| ISSN: | 1434-9949 0770-3198 |
| DOI: | 10.1007/bf02229869 |
| Popis: | Low-dose methotrexate has gained widespread acceptance as a second-line agent in rheumatoid arthritis (RA). The Leeds Human Model Screening System (LHMSS) is a validated screening mechanism allowing the rapid evaluation of compounds for their potential as anti-rheumatic agents, the results of which have been confirmed in longer term studies. We have evaluated methotrexate in patients with RA using the LHMSS at a maintenance dose of 10mg/week. Significant change occurred in four out of eleven variables over a 24-week period (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink